Impulsonics has closed its first funding round to advance the development of its unique biotech automation platform and begin customer trials.

Impulsonics is an award-winning cell technology spinout from the University of Bristol’s Ultrasonics and Non-Destructive Testing Research Group, building on over a decade of deep research and leveraging world-leading expertise in acoustics. The company joined SETsquared Bristol’s incubation programme in July 2023 as prize winner of the University of Bristol’s New Enterprise Competition.

The investment from SFC Capital, British Business Investments, the University of Bristol and private angels highlights market confidence in Impulsonics’ mission to turn cutting edge scientific innovations into scalable processes for research and healthcare.

Dr Luke Cox, CEO & Co-Founder of Impulsonics, said: “This is a really exciting time for us. We’re already seeing a demand for more reliable, scalable processes across the sector and that is exactly what our technology promises to deliver. Our unique approach builds on well-established industrial technologies from the aerospace and infrastructure sectors and will help to re-imagine workflows in biotechnology.”

Impulsonics is developing a biotech automation platform that uses acoustic waves to move cells inside sterile containers without touching them. This enables a massive reduction in the complexity of critical processes in cell culture leading enabling low cost, high throughput modular systems for automation of critical pain points.

Its technology will enable a transformation of lab-scale cell culture techniques into a reliable industrial process suitable for 21st century healthcare and drug discovery applications. This will be especially critical given the rise of AI in drug discovery which demands large volumes of high-quality data, far beyond what current processes can yield.

Learn more about Impulsonics: www.impulsonics.com

Find out more about SETsquared Bristol’s incubation programme.